Novartis receives from European Commission and MHRA to market ofatumumab (Kesimpta) for treatment of adults with relapsing forms of multiple sclerosis with active disease

Approval of this anti-CD20 monoclonal antibody is based on the two phase III ASCLEPIOS studies (n=1882), which met primary endpoint, demonstrating significant reduction in annualised relapse rate by 50.5% and 58.5% compared with teriflunomide in ASCLEPIOS I and II, respectively.

Source:

PharmaTimes